Pharmaceutical Companies

The partnership expands the use of ALT B4, a proprietary recombinant human hyaluronidase developed through Alteogen’s Hybrozyme platform.

The deal also includes up to US$1.185 billion in development, regulatory and commercial milestone payments, bringing its potential total value to US$1.295 billion.

The approach is intended to support drug discovery in neurology, where diseases often arise from complex interactions involving genetic, developmental, neural network, immune and environmental factors.

The acquisition adds rare endocrine diseases as a new growth area alongside Vertex’s existing focus on cystic fibrosis, hematology, acute pain and renal disease.

The collaboration combines Weave Bio’s artificial intelligence tools with Takeda’s regulatory expertise to simplify and speed up activities involved in preparing submissions and responding to questions from health authorities.

The meeting brings together stakeholders to discuss practical approaches to strengthening Ghana’s health system and advancing national UHC priorities.

The initiative forms part of ADCAN Pharma’s efforts to strengthen the UAE’s capacity to produce complex and specialised medicines domestically.

AusperBio will use a significant portion of the proceeds to advance AHB 137, an antisense oligonucleotide therapy for CHB, through its Phase III registrational programme and toward potential commercialisation.

Kowa is seeking approval based on results from the pivotal Phase III Mont Blanc and Denali trials.

Cushing’s syndrome of endogenous origin occurs when the body produces excessive amounts of cortisol and other steroid hormones.